Concepedia

The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

Ada Rephaeli, Michal Entin‐Meer, Dikla Angel, Nataly Tarasenko, Tal Gruss-Fischer, Irena Bruachman, Don R. Phillips, Suzanne M. Cutts, Daphne A. Haas‐Kogan, Abraham Nudelman

Investigational New Drugs · 2006 · 37 citations · 20 references

DOI

Concepts

References

20

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

William Kevin Kelly, Owen A. O’Connor, Lee M. Krug et al. · Journal of Clinical Oncology · 2005 · 907 citations · Full text

, , +16

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

Tony Reid, Frank H. Valone, William LiPera et al. · Lung Cancer · 2004 · 162 citations

, , +16

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Amita Patnaik, Eric K. Rowinsky, Miguel A. Villalona et al. · PubMed · 2002 · 124 citations

, , +11

A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro

Timothy A. McCaffrey, Lily Agarwal, Babette B. Weksler · In Vitro Cellular & Developmental Biology - Plant · 1988 · 94 citations

, , +9

Derivatives of butyric acid as potential anti‐neoplastic agents

Ada Rephaeli, Ester Rabizadeh, Adina Aviram et al. · International Journal of Cancer · 1991 · 90 citations

, , +15